Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$534M |
| 2 |
Amazon
AMZN
|
+$399M |
| 3 |
Abbott
ABT
|
+$381M |
| 4 |
Adobe
ADBE
|
+$353M |
| 5 |
Oracle
ORCL
|
+$261M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sherwin-Williams
SHW
|
+$407M |
| 2 |
Bank of America
BAC
|
+$368M |
| 3 |
TE Connectivity
TEL
|
+$366M |
| 4 |
Goldman Sachs
GS
|
+$302M |
| 5 |
Atlassian
TEAM
|
+$301M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.57% |
| 2 | Healthcare | 19.51% |
| 3 | Consumer Discretionary | 9.79% |
| 4 | Industrials | 9.79% |
| 5 | Financials | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
IDEAYA Biosciences
IDYA
$3.48B
| $126M | 0.08% |
3,551,891
+1,828,731
| +106% | +$54.6M |
|
227
nVent Electric
NVT
$22.9B
| $126M | 0.08% |
2,134,783
+536,097
| +34% | +$28.4M |
|
|
SUM
228
DELISTED
Summit Materials, Inc. Class A Common Stock
SUM
| $126M | 0.08% |
3,279,352
-490
| -0% | -$17K |
|
229
Vertiv
VRT
$104B
| $122M | 0.07% |
2,550,367
+1,499,445
| +143% | +$63.8M |
|
230
Zurn Elkay Water Solutions
ZWS
$8.23B
| $122M | 0.07% |
4,150,678
+3,743
| +0.1% | +$106K |
|
231
S&P Global
SPGI
$125B
| $122M | 0.07% |
276,300
-206
| -0.1% | -$81.3K |
|
232
BellRing Brands
BRBR
$1.59B
| $121M | 0.07% |
2,186,770
-83,140
| -4% | -$4.01M |
|
233
Williams Companies
WMB
$85.8B
| $119M | 0.07% |
3,428,898
-469,741
| -12% | -$16.5M |
|
234
Aon
AON
$81.4B
| $119M | 0.07% |
409,018
-182,747
| -31% | -$58.5M |
|
235
Clarivate
CLVT
$1.53B
| $118M | 0.07% |
12,760,671
+170,827
| +1% | +$1.26M |
|
236
Agree Realty
ADC
$9.74B
| $117M | 0.07% |
1,866,184
+570,967
| +44% | +$33.1M |
|
237
EOG Resources
EOG
$74.4B
| $117M | 0.07% |
966,486
-36,883
| -4% | -$4.59M |
|
238
AstraZeneca
AZN
$267B
| $116M | 0.07% |
864,628
-57,429
| -6% | -$7.47M |
|
239
Legend Biotech
LEGN
$3.68B
| $112M | 0.07% |
1,865,157
+131,379
| +8% | +$8.33M |
|
240
Centene
CNC
$31.6B
| $111M | 0.07% |
1,495,067
-153,745
| -9% | -$11.1M |
|
241
Zai Lab
ZLAB
$2.1B
| $110M | 0.07% |
4,040,282
-202,944
| -5% | -$5.36M |
|
242
Autodesk
ADSK
$50.1B
| $108M | 0.06% |
441,891
-4,705
| -1% | -$1.02M |
|
243
Western Alliance Bancorporation
WAL
$9.13B
| $107M | 0.06% |
1,619,120
+339,505
| +27% | +$17.1M |
|
244
Encompass Health
EHC
$11.5B
| $106M | 0.06% |
1,593,359
+21,607
| +1% | +$1.4M |
|
245
UBS Group
UBS
$171B
| $106M | 0.06% |
3,406,328
+755,403
| +28% | +$19.9M |
|
246
Saia
SAIA
$10.9B
| $105M | 0.06% |
240,131
-24,898
| -9% | -$10.1M |
|
247
Maximus
MMS
$3.31B
| $103M | 0.06% |
1,228,711
-86,722
| -7% | -$6.92M |
|
248
NeoGenomics
NEO
$1.74B
| $103M | 0.06% |
6,348,613
-825,814
| -12% | -$13.5M |
|
|
SLNO
249
DELISTED
Soleno Therapeutics
SLNO
| $102M | 0.06% |
2,523,897
+319,844
| +15% | +$9.1M |
|
|
AKRO
250
DELISTED
Akero Therapeutics
AKRO
| $101M | 0.06% |
4,306,401
-180,325
| -4% | -$3.56M |
|
Similar funds
Janus Henderson Group's Q4 2023 Portfolio in Review
As of Q4 2023, Janus Henderson Group held 2,657 positions worth $168B, up 9.8% from $153B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Janus Henderson Group's Q4 2023 filing shows 98 new, 642 increased, 1,760 reduced and 111 closed positions. Its largest new stake was Veralto: 2,881,576 shares worth $237M. The largest sale was Sherwin-Williams, an estimated $407M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 32% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Janus Henderson Group's largest Q4 2023 buy was Veralto: 2,881,576 shares worth $237M.
- Janus Henderson Group added most to Eli Lilly in Q4 2023, an estimated $534M increase.
- Janus Henderson Group's biggest Q4 2023 reduction was Sherwin-Williams, cutting an estimated $407M.
- Janus Henderson Group fully exited National Instruments Corp in Q4 2023, selling an estimated $243M.
- Janus Henderson Group's ten largest holdings make up 27% of its $168B portfolio in Q4 2023.
- Janus Henderson Group opened 98 new positions and closed 111 in Q4 2023.
- Janus Henderson Group's portfolio value rose 9.8% quarter-over-quarter to $168B.
Based on Janus Henderson Group's 13F filing for Q4 2023, filed 14 Feb 2024.